Related Experiment Video
Updated: May 8, 2026
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Targeted therapy for cancer: the gastrointestinal stromal tumor model
Vinod P Balachandran1, Ronald P Dematteo
1Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Abstract:
Gastrointestinal stromal tumors (GISTs) are unique tumors, arising largely due to oncogenic mutations in KIT or PDGFRA tyrosine kinases. Although surgery remains the most effective treatment, the remarkable clinical success achieved with kinase inhibition has made GIST one of the most successful examples of targeted therapy for the treatment of cancer. The insight gained from this approach has allowed a deeper understanding of the molecular biology driving kinase dependent cancers, and the adaptations to kinase inhibition, linking genotype to phenotype. Mutation tailored kinase inhibition with second generation TKI's, and combination immunotherapy to harness the effects of TKIs remain exciting areas of investigation.
Insights
Gastrointestinal stromal tumors (GISTs) are successfully treated with targeted kinase inhibitors due to specific mutations. Further research explores advanced inhibitors and immunotherapy for GIST treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Gastrointestinal stromal tumors (GISTs) are primarily driven by mutations in KIT or PDGFRA tyrosine kinases.
- While surgery is the primary treatment, kinase inhibitors have shown significant success, establishing GIST as a model for targeted cancer therapy.
Purpose of the Study:
- To review the molecular basis of GISTs and the impact of targeted therapies.
- To discuss the understanding of kinase-dependent cancers and adaptations to kinase inhibition.
- To highlight ongoing research in advanced kinase inhibitors and combination immunotherapy for GIST.
Main Methods:
- Review of existing literature on GIST molecular biology and targeted therapies.
- Analysis of clinical outcomes associated with kinase inhibition in GIST patients.
- Discussion of emerging therapeutic strategies, including second-generation TKIs and immunotherapy.
Main Results:
- Kinase inhibition has revolutionized GIST treatment, demonstrating the efficacy of genotype-directed therapy.
- Understanding GIST molecular drivers has deepened insights into kinase-dependent cancers.
- Adaptations to kinase inhibition and genotype-phenotype correlations are key areas of study.
Conclusions:
- Targeted kinase inhibition represents a highly successful therapeutic strategy for GIST.
- Further investigation into mutation-tailored therapies and immunotherapy combinations holds promise for improved GIST treatment outcomes.
